

Edgar Filing: BioAmber Inc. - Form 8-K

BioAmber Inc.
Form 8-K
January 30, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2017

BIOAMBER INC.

(Exact name of registrant as specified in charter)

| | | |
|------------------------------|--------------|---------------------|
| Delaware | 001-35905 | 98-0601045 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

1250 Rene Levesque West, Suite 4310

Montreal, Quebec, Canada H3B 4W8

(Address of principal executive office)

Registrant's telephone number, including area code (514) 844-8000

Not Applicable

Edgar Filing: BioAmber Inc. - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.02 Termination of a Material Definitive Agreement

On January 27, 2017, the Company paid off and terminated its demand non-revolving credit facility agreement (the “Facility Agreement”) with Bridging Finance Inc. The Company reimbursed the CDN\$ 25 million principal owed, as well as accrued and unpaid interest and fees. As a result of the repayment, Bridging Finance Inc. is required to terminate its security interest in the corporate level assets of the Company, according to the terms contained in the Facility Agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOAMBER INC.

Date: January 30, 2017 By: /s/ Jean-François Huc
Jean-François Huc, Chief Executive Officer